Advanced/metastatic soft tissue sarcomas (STS) remain an unmet clinical need. We previously reported the feasibility and preliminary activity of trabectedin-olaparib combination in patients with advanced STS progressing after anthracycline-based regimens.
Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase 2 study from the Italian Sarcoma Group
Annals of Oncology | | L. D’Ambrosio, A. Merlini, A. Brunello, V. Ferraresi, A. Paioli, B. Vincenzi, M.A. Pantaleo, T.M. De Pas, L. Gurrieri, R. Sanfilippo, A. Buonadonna, G.G. Baldi, G. Badalamenti, C. Marchiò, Y. Pignochino, E. Berrino, S.E. Bellomo, M. Sbaraglia, L. Righi, M. Rabino, F. Tolomeo, S. Aliberti, D. Sangiolo, A.P.Dei Tos, S. Stacchiotti, G. Grignani
Topics: sarcoma, chemotherapy, clinical-trials, research